With our proprietary phosphorylated tau 217 (pTau217) blood-based biomarker, ALZpathDx offers an approach to early diagnosis that is simple, accessible, timely, cost-effective and less invasive than current testing methods.
pTau217 in blood is a transformative Alzheimer’s disease diagnostic biomarker, which closely reflects amyloid and tau pathology, the hallmarks of Alzheimer’s, and correlates with clinical features of Alzheimer’s disease.